David M. Epstein - 27 Jun 2023 Form 4 Insider Report for Black Diamond Therapeutics, Inc. (BDTX)

Reporting relationship
Officer Title: President and Chief Executive Officer, Director
Issuer ticker
BDTX
Reported as of
27 Jun 2023
Net transaction value
-$167,500
Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
28 Jun 2023, 16:02:20 UTC
Prior SEC filing
15 Feb 2023
Next SEC filing
08 Aug 2024
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Brent Hatzis-Schoch, Attorney-in-Fact

Key filing fact

David M. Epstein filed Form 4 for Black Diamond Therapeutics, Inc. (BDTX) on 28 Jun 2023.

Key facts

  • This page summarizes David M. Epstein's Form 4 filing for Black Diamond Therapeutics, Inc. (BDTX).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Accepted by SEC: 28 Jun 2023, 16:02.

Change

  • Previous filing in this sequence was filed on 15 Feb 2023.
  • Current net transaction value: -$167,500.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BDTX transaction

Common Stock

Sale

Transaction value
$167,500
Shares
-25,000
Change %
-3.6%
Price
$6.70
Shares after
671,423
Date
27 Jun 2023
Ownership
Direct
Footnotes
F1
BDTX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
23,090
Date
27 Jun 2023
Ownership
See footnote
Footnotes
F2
BDTX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
104,449
Date
27 Jun 2023
Ownership
See footnote
Footnotes
F3
BDTX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
104,449
Date
27 Jun 2023
Ownership
See footnote
Footnotes
F4
BDTX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
16,579
Date
27 Jun 2023
Ownership
See footnote
Footnotes
F5
BDTX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
16,579
Date
27 Jun 2023
Ownership
See footnote
Footnotes
F6
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 6 footnotes

Footnote F1

Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of December 29, 2022.

Footnote F2

Shares held by wife.

Footnote F3

Shares held by David M. Epstein 2019 Trust For Elle. David M. Epstein is the trustee of the David M. Epstein 2019 Trust for Elle and may be deemed to beneficially own these securities.

Footnote F4

Shares held by David M. Epstein 2019 Trust For Zoe. David M. Epstein is the trustee of the David M. Epstein 2019 Trust for Zoe and may be deemed to beneficially own these securities.

Footnote F5

Shares held by David M. Epstein 2019 Trust For Robert. David M. Epstein is the trustee of the David M. Epstein 2019 Trust for Robert and may be deemed to beneficially own these securities.

Footnote F6

Shares held by David M. Epstein 2019 Trust For Shelley. David M. Epstein is the trustee of the David M. Epstein 2019 Trust for Shelley and may be deemed to beneficially own these securities.

SEC remarks

Officer Title: President and Chief Executive Officer

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .